Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096, Warsaw, Poland.
Department of Molecular and Translational Oncology, Maria Skłodowska-Curie Institute - Oncology Center, Roentgena 5, 02-781, Warsaw, Poland.
Med Oncol. 2018 Mar 8;35(4):49. doi: 10.1007/s12032-018-1111-x.
The main cause of death in mantle cell lymphoma (MCL) patients is relapse due to undetermined minimal residual disease (MRD) and therefore monitoring MRD is crucial for making the best treatment decisions. The gold standard method for MRD analysis is the quantitative polymerase chain reaction. The most commonly used molecular markers for measuring MRD in MCL are: t(11;14)(q13;p32) translocation or CCND1 expression and IGH rearrangement. Such markers can, however, be found in other B cell non-Hodgkin lymphomas. Recent studies demonstrate that SOX11 expression is highly specific for MCL and could be used as a marker for measuring MRD. Moreover, evidence shows that SOX11 level could be predictive for overall survival (OS) and progression-free survival (PFS). We have measured MRD level in follow-up samples from 27 patients diagnosed with MCL using the molecular markers: t(11;14), IGH rearrangement and SOX11 expression. We compared all markers by their sensitivity, utility and quantitative range. We also examined the predictive value of SOX11 expression for OS and PFS. SOX11 expression was found to have better specificity, quantitative range and utility than the t(11;14). The predictive value of SOX11 expression was confirmed. At diagnosis, patients with high SOX11 expression had shorter PFS than patients with low SOX11 expression (p = 0.04*); differences between OS being statistically insignificant. To our best knowledge this is a first study comparing SOX11 with t(11;14) and IGH rearrangement as markers of MRD level. Moreover, in this study we confirmed that SOX11 is useful in cases when other molecular markers cannot be used.
套细胞淋巴瘤（MCL）患者的主要死亡原因是由于未确定的微小残留病（MRD）而复发，因此监测 MRD 对于做出最佳治疗决策至关重要。MRD 分析的金标准方法是定量聚合酶链反应。用于测量 MCL 中 MRD 的最常用分子标志物是：t(11;14)(q13;p32)易位或 CCND1 表达和 IGH 重排。然而，这些标志物也可以在其他 B 细胞非霍奇金淋巴瘤中发现。最近的研究表明，SOX11 表达高度特异性地针对 MCL，可以用作测量 MRD 的标志物。此外，有证据表明 SOX11 水平可预测总生存期（OS）和无进展生存期（PFS）。我们使用分子标志物：t(11;14)、IGH 重排和 SOX11 表达，在 27 例诊断为 MCL 的患者的随访样本中测量了 MRD 水平。我们比较了所有标志物的敏感性、实用性和定量范围。我们还检查了 SOX11 表达对 OS 和 PFS 的预测价值。SOX11 表达的特异性、定量范围和实用性均优于 t(11;14)。SOX11 表达的预测价值得到了证实。在诊断时，SOX11 高表达的患者的 PFS 短于 SOX11 低表达的患者（p=0.04*）；OS 之间的差异无统计学意义。据我们所知，这是首次将 SOX11 与 t(11;14)和 IGH 重排作为 MRD 水平的标志物进行比较的研究。此外，在本研究中，我们证实 SOX11 在其他分子标志物无法使用的情况下是有用的。
